Skip to main content
QNRX logo

QNRX · Quoin Pharmaceuticals Ltd.

Track QNRX — free
$3.36 -0.20 (-5.64%) At close · Nov 19
Market Cap
$16.14M
Shares
4.80M
Volume · Nov 19 11.06K Avg daily vol (3M) 534.28K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$3.36 Open$3.46 Day$3.30–3.56 52W close$3.25–22.30 Avg vol 30d20K Short int24K · 0.5% of shares · 1.9d Short vol65% Last earningsMay 7, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 5

Up next

call held Mar 14, 2024

Latest documents

2026
Nov 12
Current report 8-K
Shareholders approve investor ownership cap of 9.99%

At Quoin Pharmaceuticals Ltd.’s Special General Meeting on November 12, 2026, shareholders approved raising applicable investor ownership limits from 4.99% to as much as 9.99% and authorized an adjournment if needed.

Shareholder vote results
3 source passages
Quoin Pharmaceuticals Ltd. (“we,” “us,” or the “Company”) held a Special General Meeting of Shareholders (the “Special Meeting”) on November 12, 2026. The shareholders approved a proposal to amend the beneficial ownership limitations imposed on each investor in the transaction documents entered into in connection with the Company’s private placement transactions consummated on October 14, 2025 and August 31, 2026, as applicable, to permit each such investor, upon written notice to the Company, to increase its applicable beneficial ownership limitations (including any corresponding limitations on voting power) from 4.99% to any percentage not exceeding 9.99% of the number of the Company’s outstanding Ordinary Shares (including Ordinary Shares represented by ADSs), determined immediately after giving effect to the issuance of the applicable securities, for purposes of both Section 13(d) of the Securities Exchange Act of 1934, as amended, and Section 270(5) and Section 274 of the Israeli Companies Law, 5759-1999, as described in the Proxy Statement, based upon the following votes: The shareholders approved an adjournment of the Special Meeting to a later date, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there were insufficient votes for, or otherwise in connection with, the approval of Proposal 1, based upon the following votes: Open the document at this passage
Nov 6
Current report 8-K Events of Nov 5
QRX003 Interim Data Meets Primary and Key Secondary Endpoints

Quoin Pharmaceuticals Ltd. reported statistically significant interim Phase 2/3 QRX003 results in Netherton Syndrome, including 66.7% achieving the primary endpoint, alongside a private placement for up to approximately $50.0 million.

Financial results
3 source passages
Positive Interim Data from Phase 2/3 Study CL-QRX003-004. On August 28, 2026, Quoin reported positive interim results from CL-QRX003-004, its ongoing Phase 2/3 study of QRX003 4% lotion in patients with Netherton Syndrome. In the interim analysis of the first six participants to complete 12 weeks of treatment, four of six (66.7%) achieved the primary endpoint of a 1-grade or greater improvement in Investigator Global Assessment (p=0.0087 vs. a pre-specified alpha of 0.0215). The key secondary endpoint, a Global Statistical Test of Global Impression of Change, also achieved statistical significance at Week 12 (p=0.0070 vs. a pre-specified alpha of 0.0215). On August 28, 2026, Quoin announced a private placement with new and existing healthcare-focused institutional investors for up to approximately $50.0 million in gross proceeds, including initial upfront funding of approximately $30.8 million and up to an additional approximately $19.2 million upon the potential cash exercise of accompanying ordinary warrants. Open the document at this passage
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
QRX003 reports positive interim Netherton Syndrome data

Quoin reported positive interim QRX003 data in Netherton Syndrome; four of six participants achieved target 1-grade or greater improvement at week 12. It also launched a $11,000,000 ATM offering on November 4, 2026.

Net loss $4.87M
Read from the MD&A section
3 source passages
On August 28, 2026, we reported positive interim data from our ongoing Phase 2/3 study of QRX003 in NS. Four of six participants achieved the target 1-grade or greater improvement in investigator global assessment at week 12 (p=0.0087) with statistical significance versus the pre-specified alpha of 0.0215. On November 4, 2026, the Company entered into a Sales Agreement (the “Sales Agreement”) with Leerink Partners, LLC, as sales agent (the “Sales Agent” or “Leerink Partners”), to sell Ordinary Shares represented by ADSs from time to time in an “at the market offering” program through Leerink Partners. The aggregate market value of the ADSs eligible for sale under the prospectus supplement is currently $11,000,000, which is based on the limitations of General Instruction I.B.6 of Form S-3. Open the document at this passage
Nov 4
Current report 8-K
Quoin enters Leerink at-the-market ADS sales agreement

Quoin Pharmaceuticals Ltd. entered a sales agreement with Leerink Partners LLC on November 4, 2026, enabling at-the-market sales of ADSs, each representing 35 ordinary shares, with a 3.0% commission on gross proceeds.

Entered into a material agreement Read from the first part of this long document
2 source passages
On November 4, 2026, Quoin Pharmaceuticals Ltd. (the “Company” or “Quoin”) entered into a sales agreement (the “Sales Agreement”) with Leerink Partners LLC (“Leerink Partners”), pursuant to which the Company may sell, from time to time, American Depositary Shares (“ADSs”), each representing 35 of the Company’s ordinary shares, no par value (“Ordinary Shares”), through Leerink Partners, acting as agent. Under the Sales Agreement, the Leerink Partners will be entitled to compensation of 3.0% of the gross sale proceeds of all ADSs sold through it pursuant to the Sales Agreement. Open the document at this passage
Oct 28
Registration statement S-3
Shelf registration for up to $150,000,000 in securities

Quoin Pharmaceuticals Ltd. filed a shelf registration statement allowing it to offer up to $150,000,000 in ordinary shares represented by ADSs, warrants, subscription rights, debt securities and units. As of October 23, 2026, the public float was approximately $36,422,384, and while it remains below $75.0 million, the company may not sell securities in a public primary offering exceeding more than one-third of that float in any 12-month period.

Read from the first part of this long document
3 source passages
We may, from time to time, offer and sell up to $150,000,000 in the aggregate, of our ordinary shares represented by American Depositary Shares As of October 23, 2026, the aggregate market value of our outstanding ordinary shares represented by ADSs held by non-affiliates, or public float, was approximately $36,422,384 in no event will we sell securities registered on this registration statement, of which any prospectus supplement forms a part, in a public primary offering with a value exceeding more than one-third of our public float in any 12-month period so long as our public float remains below $75.0 million Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$19.59M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$33.18M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+716.8%
Year over year · more shares
Price change (1Y)
-81.5%
Trailing year
Short interest
0.5%
Latest settlement · 1.9 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Bullish Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −41%
below
Price vs 50-day avg −29%
below
RSI (14) 34
neutral
MACD trend Positive
52-week position 1%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −16%
trailing
6-month return −30%
trailing
YTD return −77%
this year
Relative strength −24%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $5 › 200d $6 — 200d above 50d
Institutional flow Accumulating
+32% holders QoQ · +15 funds added
Insider flow Accumulating
Net +$280.0K over 90 days · 0% sells
Short interest Rising
0.49% of shares out · ▲ +17.2% MoM · 1.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
25 holders — near 3-yr high, broad support
Squeeze score 44
elevated · 0–100
Fundamentals
Excellent
EPS growth +99%
Y/Y
Balance sheet $3.8M
net cash
Quant / Vol
risk profile
Very High
Volatility 107%
annualized · 1-yr
Max drawdown −85%
past year
ATR 9.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−41% Bearish
Price vs 50-day avg
−29% Bearish
RSI (14)
34 Neutral
MACD trend
Positive Bullish
52-week position
1% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $5 › 200d $6 — 200d above 50d
Institutional flow Accumulating
+32% holders QoQ · +15 funds added
Insider flow Accumulating
Net +$280.0K over 90 days · 0% sells
Short interest Rising
0.49% of shares out · ▲ +17.2% MoM · 1.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
25 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $3 Now $3 · 1% Range high $22
vs 200-day avg -41% vs 50-day avg -29%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
IGA score 0 by eight months —
initial upfront funding $30.8M August 28, 2026 —
key secondary endpoint 0.01 Week 12 —
NETHERTON NOW series impressions 28M September 10, 2026 —
NETHERTON NOW series views 2.8M September 10, 2026 —
participants with moderate to severe pruritus at baseline achieving a 3-grade or greater improve 3 Week 12 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
QNRX
Quoin Pharmaceuticals Ltd.
this stock
$16.14M -76.7% — — 0.5%
VRTX
Vertex Pharmaceuticals Inc
$132.01B +14.8% +46.2% 33.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.52B +19.6% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$80.65B +575.9% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.15B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
25
% held
55.7%
Net QoQ
+1.4M sh
Top holder
Stonepine Capital Managem…
Held Float
View
Held by Funds
Fund positions
2
View
Short & Settlement
Short Interest Rising
Shares short
23.7K
Days to cover
1.9d
Change
+3.5K sh
View
Short Volume
Short vol %
65%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
774
Value
$3.2K
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
37.1%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Cluster buy
Net (90d)
+$280.0K
Buyers / Sellers
4 / 0
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$0
Net income (FY)
$-15.8M
EPS diluted
$-52.50
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 12, 2026
This year
27

At Quoin Pharmaceuticals Ltd.’s Special General Meeting on November 12, 2026, shareholders approved raising applicable investor ownership limits from 4.99% to as much as 9.99% and authorized an adjournment if needed.

View
Proposed Sales
Value
$218
Shares
297
Filed
Jun 7, 2024
View
Exempt Offerings
Offering
$50.0M
Filed
Sep 10, 2026
View
Earnings & Events
Webcasts
Last webcast
May 7, 2026
View
Investor Relations
Latest news
Quoin Pharmaceuticals’ Latest NET…
Published
Nov 6, 2026
View

Performance

5D 20D 120D MTD YTD
QNRX -10.4% -16.2% -29.6% -26.0% -76.7%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY -5.0% -9.9% -24.0% -20.7% -81.7%
Key facts CIK 1671502 CUSIP 74907L409 13F (30d) 24 filings 24 filers Visit website Investor relations